The dysregulation and activation of the MAPK1/3 signaling pathway have been strongly correlated with the initiation and progression of diverse tumors (45–47), including but not limited to lung cancer (48), breast cancer (49), and liver cancer (50). This evidence concerns the gene MAPK1 and breast carcinoma.